Abstract
Invasive candidiasis is an infrequent, yet life-threatening infection among HIV-infected children. The treatment of choice are amphotericin B formulations and alternatively fluconazole. Good penetration to the central nervous system of both drugs makes such therapy a reasonable solution for this specific group of patients. Echinocandins, mainly due to their outstanding safety profile, alongside with clinical effectiveness, are still a second-line treatment and further research is required to assess their role as antifungal agents used in management of Candida infections in HIV-infected children. However, they are the first-line antifungal agents in other groups of patients according to recently published guidelines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
